Annals of Health Law

Volume 26
Issue 1 *Winter 2017*

Article 1

2017

Table of Contents

Annals of Health Law

ANNALS OF HEALTH LAW

THE HEALTH POLICY AND LAW REVIEW OF
LOYOLA UNIVERSITY CHICAGO SCHOOL OF LAW

Beazley Institute for Health Law and Policy

VOLUME 26, ISSUE 1 WINTER 2017

CONTENTS

Inappropriate and underregulated use of antibiotics threaten public health by increasing antibiotic resistance of bacterial infections, and in turn, making them more difficult to treat. This article emphasizes the need for legally binding standards to reduce misuse and stimulate the development of antibiotic drugs. It suggests that the Food and Drug Administration (FDA) impose a Risk Evaluation and Mitigation Strategy (REMS) restriction on novel antibiotic drug products to conserve their use and prevent misuse. Further, this article urges Congress to implement statutory reform to incentivize innovation in antibiotic development. Passing new statutory and regulatory guidelines will take time, coordination, and perseverance. Until a new regulatory regime surrounding antibiotics is established, policymakers should work within existing statutory frameworks to curb resistance by using the Orphan Drug Act (ODA) to spur antibiotic innovation and the Controlled Substance Act (CSA) to promote antibiotic conservation.